Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41712| metadata.artigo.dc.title: | As a potential treatment of COVID-19: Montelukast |
| metadata.artigo.dc.creator: | Fidan, Cihan Aydoğdu, Ayşe |
| metadata.artigo.dc.publisher: | Elsevier |
| metadata.artigo.dc.date.issued: | Sep-2020 |
| metadata.artigo.dc.identifier.citation: | FIDAN, C.; AYDOĞDU, A. As a potential treatment of COVID-19: Montelukast. Medical Hypotheses, [S.l.], v. 142, Sept. 2020. |
| metadata.artigo.dc.description.abstract: | It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection. |
| metadata.artigo.dc.identifier.uri: | https://www.sciencedirect.com/science/article/pii/S0306987720306368 http://repositorio.ufla.br/jspui/handle/1/41712 |
| metadata.artigo.dc.language: | en_US |
| Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.